Vision 2030 is creating greater stakeholder alignment, and making Saudi Arabia a more attractive destination for pharma industry investment, especially in clinical trials at this stage,…
In Conversation
Celltrion is a true pioneer in biosimilars. Our objective at the moment is to launch at least one product per year; we try to be very…
The opportunities [in Saudi Arabia] are heightened by the leadership in the country and its Vision 2030; it encourages investment and favours private partnerships
We are not only working to localize manufacturing but also actively driving knowledge transfer for local professionals; the goal is to help them comply with the…
Saudi Arabia is one of the most important and strategic markets in the region. The Kingdom is clearly committed to bettering the health of its citizens…
Agility is of paramount importance and the COVID-19 pandemic has engendered huge changes in market dynamics
Polifarma is a secure port and a trusted partner because we are transparent and take care of our customers and suppliers
Turkey has become a regional hub in terms of R&D, design, production, logistics and management for investors especially in the life sciences industry because of the…
When it comes to value-based care, Saudi Arabia is still at an early phase, but we are on the right track. We expect the local healthcare…
While scaling our company by uniting with others would make us more competitive on a global scale, we still believe it is possible to be successful…
The main differentiating factor for Abdi Ibrahim among Turkish companies is our willingness to invest in, and collaborate with, international players
We are close to having the technological capacity to develop all types of biosimilar products, even some novel ones
